Rybelsus safety check in routine diabetes care in Korea
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tracks how Rybelsus (oral semaglutide) works and how safe it is for people with type 2 diabetes in everyday clinic use in Korea. It doesn’t change your treatment plan—it follows people who and their doctors choose to start Rybelsus normally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are planning to start commercially available Rybelsus by your doctor before joining the study
- You must have a planned start for Rybelsus for type 2 diabetes based on the approved Korea label
- You (or your legally acceptable representative) can sign informed consent before any study procedures
- You are at least 19 years old when you sign consent
- You have not taken Rybelsus before and you haven’t joined this study before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how Ozempic works and whether it stays safe for people with type 2 diabetes in everyday clinic care in Korea. You join because your doctor decides you should start Ozempic, and the study mainly monitors outcomes.
This trial tests if semaglutide, a diabetes and weight-loss medication, can improve psoriasis symptoms and reduce inflammation. It may be an option for people with both psoriasis and overweight or obesity, with or without diabetes.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This trial tests a new medication, QLG1091, compared to a standard pill (Rybelsus) for people with type 2 diabetes who are already taking metformin. It aims to see which works better to control blood sugar.
This study watches how Wegovy (semaglutide) works and its side effects when given by doctors to patients with obesity or overweight in South Korea. It is not testing a new drug, but collecting information from routine care.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.